Sign up
Pharma Capital

Avacta Group Plc making 'excellent progress' on lead programmes

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive Investors their lead PD-L1 programme remains on track to deliver key pre-clinical milestones this year.

Smith says they're also making “excellent progress” with a second immuno-oncology research project, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.

Avacta, in its half-year results update, said its discovery programme continued to deliver a pipeline of binders to other important immuno-oncology targets for future partnering or development.

 

View full AVCT profile View Profile
CN Video

Riccardo Lowi discusses Avacta

CN Research

Avacta Group Plc - On track and undervalued

View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.